Guido Eibl

1.8k citations
31 papers · 1.5k indexed · h-index 18

Impact in

    • MicroRNA in disease regulation
    • Cancer Genomics and Diagnostics
  • Oncology top 5%
    • Pancreatic and Hepatic Oncology Research

Papers in

    • Flavonoids in Medical Research 6
    • Inflammatory mediators and NSAID effects 4
    • Berberine and alkaloids research 2
    • Cancer, Lipids, and Metabolism 4

Guido Eibl

31 papers receiving 1.4k citations

Peers

Guido Eibl
Comparison fields: 5 of 93
  • Cancer Research 396
  • Oncology 531
  • Pharmacology 242
  • Biochemistry 64
  • Molecular Biology 723
Replace Addanki P. Kumar with:
Addanki P. Kumar United States
Yayun Liang United States
Alexandra S. Bause United States
Zebo Jiang China
Malisetty V. Swamy United States
Sung Hoo Jung South Korea
Mohammad R. Salabat United States
Huanjie Shao China
Keyuan Zhou China
Nagalakshmi Nadiminty United States
Guido Eibl relative to Addanki P. Kumar United States Addanki P. Kumar's profile →
Citations per field
00.5×1.5×
Addanki P. Kumar · 1×
Citations per year

Countries citing papers authored by Guido Eibl

Since Specialization
Citations

This map shows the geographic impact of Guido Eibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Eibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Eibl more than expected).

Fields of papers citing papers by Guido Eibl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guido Eibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Eibl. The network helps show where Guido Eibl may publish in the future.

Co-authors

The 25 scholars most cited alongside Guido Eibl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Guido Eibl Line = papers co-authored together Guido Eibl links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 202113
2 201814
3 201511
4 2013205
5 201343
6 2012108
7 201293
8 20122
9 20121
10 201179
11 2011153
12 201156
13 201138
14 201024
15 201026
16 20091
17 200851
18 200870
19 200837
20 200579

About Guido Eibl

Guido Eibl is a scholar working on Pharmacology, Cancer Research, Oncology, Toxicology and Molecular Biology, having authored 31 papers that have together received 1.5k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (7 papers), Flavonoids in Medical Research (6 papers), Cancer Mechanisms and Therapy (4 papers), Cancer, Lipids, and Metabolism (4 papers), Natural product bioactivities and synthesis (4 papers), Inflammatory mediators and NSAID effects (4 papers), Berberine and alkaloids research (2 papers) and Extracellular vesicles in disease (2 papers). The work is most often cited by research in Cancer Research (396 citations), Oncology (531 citations), Pharmacology (242 citations), Biochemistry (64 citations) and Molecular Biology (723 citations). Guido Eibl has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include O. Joe Hines, Howard A. Reber, Anna S. Gukovskaya, Eliane Angst, Vay Liang W. Go, Aune Moro, David W. Dawson, Xuyang Lu, Kathleen M. Hertzer and Graham Donald. Their work appears in journals such as Pancreas, Gastroenterology, Surgery, Journal of Surgical Research and Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026